Login
$JANX
$11.12 +$0.20 (1.83%) After hours

$JANX 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 to be presented during an investor webcast on November 9, 2026

06 Aug 2026 8-K: Results of Operations and Financial Condition

JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts

23 Jun 2026 8-K: Other Events

On June 23, 2026, William Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc. (the "Company") under circumstances that the Company determined to constitute a termination without “Cause” under the terms of the Co...

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, Janux Therapeutics, Inc. (the “Company”) held the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 17, 2026, the record date for the Annual Meeting, 60,961,546 shares of common stock wer...

07 May 2026 8-K: Results of Operations and Financial Condition

JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide

28 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

In order to achieve a more equal balance of membership among the three classes of directors on the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), the Board determined that one of its members should be recla...

26 Feb 2026 8-K: Results of Operations and Financial Condition

Continued clinical execution across TRACTr programs JANX007 and JANX008

22 Jan 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

06 Nov 2025 8-K: Results of Operations and Financial Condition

Updates on JANX007 and JANX008 expected in the fourth quarter of 2025

19 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

Byron Robinson, Ph.D., previously a named executive officer of Janux Therapeutics, Inc. (the “Company”), ceased to serve as Chief Strategy Officer of the Company and departed from the Company effective September 18, 2025 under circumstan...

07 Aug 2025 8-K: Results of Operations and Financial Condition

R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases

13 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2025, Janux Therapeutics, Inc. (the “Company”) held the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 17, 2025, the record date for the Annual Meeting, 59,168,490 shares of common stock wer...

08 May 2025 8-K: Results of Operations and Financial Condition

Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients

27 Feb 2025 8-K: Results of Operations and Financial Condition

Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC

05 Dec 2024 8-K: Other Events

Pre-Funded Warrants to Purchase 238,095 Shares of Common Stock

02 Dec 2024 8-K: Regulation FD Disclosure; Other Events

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

06 Nov 2024 8-K: Results of Operations and Financial Condition

Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors

07 Aug 2024 8-K: Results of Operations and Financial Condition

Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors

22 Jul 2024 8-K: Departure/Election of Directors or Officers; Compensation

The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy

28 Jun 2024 8-K: Submission of Matters to a Vote of Security Holders

On June 26, 2024, Janux Therapeutics, Inc. (the “Company”) held the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 29, 2024, the record date for the Annual Meeting, 51,850,667 shares of common stock wer...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support